These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 3718817

  • 1. 9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures.
    Scott CA, Westmacott D, Broadhurst MJ, Thomas GJ, Hall MJ.
    Br J Cancer; 1986 May; 53(5):595-600. PubMed ID: 3718817
    [Abstract] [Full Text] [Related]

  • 2. Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A.
    Coley HM, Twentyman PR, Workman P.
    Cancer Chemother Pharmacol; 1989 May; 24(5):284-90. PubMed ID: 2547527
    [Abstract] [Full Text] [Related]

  • 3. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
    Umezawa K, Kunimoto S, Takeuchi T.
    Biomed Pharmacother; 1987 May; 41(5):206-13. PubMed ID: 2444279
    [Abstract] [Full Text] [Related]

  • 4. Evidence of multifactorial mechanisms in an adriamycin-resistant HL-60 promyelocytic leukemia cell line.
    Burres NS, Myers MT, Sartorelli AC.
    Cancer Biochem Biophys; 1988 Jul; 10(1):47-57. PubMed ID: 3224331
    [Abstract] [Full Text] [Related]

  • 5. Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines.
    Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Kimura I.
    Acta Med Okayama; 1992 Aug; 46(4):249-56. PubMed ID: 1442149
    [Abstract] [Full Text] [Related]

  • 6. [New anthracycline antibiotics and derivatives].
    Tatsuta K.
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2640-52. PubMed ID: 6594977
    [Abstract] [Full Text] [Related]

  • 7. Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.
    Hill BT, Dennis LY, Li XT, Whelan RD.
    Cancer Chemother Pharmacol; 1985 Dec; 14(3):194-201. PubMed ID: 3858013
    [Abstract] [Full Text] [Related]

  • 8. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance.
    Coley HM, Twentyman PR, Workman P.
    Anticancer Drug Des; 1992 Dec; 7(6):471-81. PubMed ID: 1337431
    [Abstract] [Full Text] [Related]

  • 9. Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues.
    Trevino AV, Woynarowska BA, Herman TS, Priebe W, Woynarowski JM.
    Mol Cancer Ther; 2004 Nov; 3(11):1403-10. PubMed ID: 15542779
    [Abstract] [Full Text] [Related]

  • 10. Inhibitory activity of four demethoxy fluorinated anthracycline analogs against five human-tumor cell lines.
    Horton D, Khare A.
    Bioorg Med Chem Lett; 2010 Nov 01; 20(21):6179-81. PubMed ID: 20850305
    [Abstract] [Full Text] [Related]

  • 11. Potentiation of adriamycin accumulation and effectiveness in adriamycin-resistant cells by aclacinomycin A.
    Tapiero H, Boulé D, Trincal G, Fourcade A, Lampidis TJ.
    Leuk Res; 1988 Nov 01; 12(5):411-8. PubMed ID: 3164087
    [Abstract] [Full Text] [Related]

  • 12. Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin.
    Hong WS, Jung HY, Yang SK, Kim HR, Min YI.
    Anticancer Res; 1997 Nov 01; 17(5A):3613-6. PubMed ID: 9413212
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
    Watanabe M, Komeshima N, Nakajima S, Tsuruo T.
    Cancer Res; 1988 Dec 01; 48(23):6653-7. PubMed ID: 3180075
    [Abstract] [Full Text] [Related]

  • 15. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N.
    Cancer Res; 1989 Aug 01; 49(15):4098-102. PubMed ID: 2472873
    [Abstract] [Full Text] [Related]

  • 16. [Studies on the mechanism of drug resistance in tumor cells and a new antitumor antibiotic].
    Tanaka N.
    Gan To Kagaku Ryoho; 1984 Dec 01; 11(12 Pt 2):2666-73. PubMed ID: 6210060
    [Abstract] [Full Text] [Related]

  • 17. The in vitro effects and cross-resistance patterns of some novel anthracyclines.
    Twentyman PR, Fox NE, Wright KA, Workman P, Broadhurst MJ, Martin JA, Bleehen NM.
    Br J Cancer; 1986 May 01; 53(5):585-94. PubMed ID: 3459509
    [Abstract] [Full Text] [Related]

  • 18. N-benzyladriamycin-14-valerate (AD 198)-resistant cells exhibit highly selective cross-resistance to other anthracyclines that circumvent multidrug resistance.
    Lothstein L, Hosey LM, Sweatman TW, Koseki Y, Dockter M, Priebe W.
    Oncol Res; 1993 May 01; 5(6-7):229-34. PubMed ID: 7907237
    [Abstract] [Full Text] [Related]

  • 19. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
    Son YS, Suh JM, Ahn SH, Kim JC, Yi JY, Hur KC, Hong WS, Muller MT, Chung IK.
    Cancer Chemother Pharmacol; 1998 May 01; 41(5):353-60. PubMed ID: 9523730
    [Abstract] [Full Text] [Related]

  • 20. Studies on aclacinomycin A resistance in mouse lymphoblastoma.
    Nishimura T, Suzuki H, Muto K, Tanaka Y, Tanaka N.
    J Antibiot (Tokyo); 1980 Jul 01; 33(7):737-43. PubMed ID: 6931828
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.